Immunome (NASDAQ:IMNM) Now Covered by Analysts at JPMorgan Chase & Co.

Stock analysts at JPMorgan Chase & Co. started coverage on shares of Immunome (NASDAQ:IMNM) in a report issued on Tuesday, Briefing.com reports. The firm set an “overweight” rating and a $24.00 price target on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 73.66% from the company’s previous close.

A number of other research analysts also recently issued reports on the company. Wedbush boosted their price objective on Immunome from $27.00 to $33.00 and gave the company an “outperform” rating in a research note on Monday, April 1st. Leerink Partnrs reiterated an “outperform” rating on shares of Immunome in a research note on Monday, January 29th. Guggenheim initiated coverage on Immunome in a research note on Monday, April 15th. They issued a “buy” rating and a $35.00 price target for the company. Finally, SVB Leerink initiated coverage on Immunome in a research note on Monday, January 29th. They issued an “outperform” rating and a $30.00 price target for the company. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $30.50.

Immunome Trading Up 0.7 %

Shares of NASDAQ:IMNM opened at $13.82 on Tuesday. The stock has a 50 day moving average of $21.76 and a 200 day moving average of $15.24. The company has a market cap of $824.92 million, a PE ratio of -2.56 and a beta of 1.66. Immunome has a 12-month low of $4.44 and a 12-month high of $30.96.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.26). The company had revenue of $3.83 million for the quarter, compared to the consensus estimate of $3.40 million. Immunome had a negative net margin of 761.92% and a negative return on equity of 69.74%. Equities research analysts predict that Immunome will post -1.91 earnings per share for the current fiscal year.

Institutional Trading of Immunome

Several hedge funds and other institutional investors have recently bought and sold shares of IMNM. TD Asset Management Inc purchased a new stake in Immunome during the 3rd quarter valued at $1,063,000. Dorsey Wright & Associates purchased a new stake in Immunome during the 3rd quarter valued at $26,000. Acadian Asset Management LLC purchased a new stake in Immunome during the 3rd quarter valued at $414,000. Cerity Partners LLC purchased a new stake in Immunome during the 4th quarter valued at $656,000. Finally, Emfo LLC purchased a new stake in Immunome during the 4th quarter valued at $633,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.